<DOC>
	<DOCNO>NCT01408199</DOCNO>
	<brief_summary>Cutaneous Lupus frequent . Approximately 70 % patient SLE develop cutaneous involvement point course disease . In spite esthetic consequence acute phase , main problem still relate disfigure incapacitating nature . Topical steroid and/or antimalarial therapy continue conventional therapy . Unfortunately , approximately 30 % refractory measure . For patient , immunosuppressive therapy alternative controversial result . Several series show 90 % clinical efficacy patient treat Thalidomide . Unfortunately , main drawback serious described side effect fetal malformation , polyneuropathy drowsiness . Recently , new thalidomide analogue , potent , efficient good safety profile discover . The main objective study evaluate efficacy safety Lenalidomide patient Refractory cutaneous Lupus . Secondary objective include evaluate effect drug systemic manifestation lupus disease , adverse effect , frequency flare withdrawal , sequela effect seric parameter . Methods : Twelve patient refractory cutaneous lupus include . Lenalidomide start 5mg/day taper progressively . Blood test EMG perform onset end follow .</brief_summary>
	<brief_title>Study To Evaluate The Safety And Efficacy Of Lenalidomide For Refractory Cutaneous Lupus</brief_title>
	<detailed_description />
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>Age 18 year Histologically proven cutaneous lupus erythematosus without associate systemic disease Presence least grade II erythema assess validate modified Cutaneous Lupus Erythematosus Disease Area Severity Index ( CLASI ) Cutaneous lesion involve 18 % body surface calculate accord rule nine , history severe side effect lack efficacy follow thalidomide therapy , cutaneous lupus disease refractory conventional treatment antimalarial topical steroid . No pregnancy wish become pregnant study period . Pregnancy , breastfeed use adequate contraception . Severe thrombocytopenia ( &lt; 30x10E9 cells/L ) leucopoenia ( &lt; 1500x10E9 ) , know least 30 day prior onset study , Previous history arterial/venous thrombosis , Presence antiphospholipid antibody Presence moderatesevere renal impairment ( FG &lt; 30 ml/min ) Progressive renal disease . Lack write informed consent prior participation study . Presence concomitant systemic flare may require systemic treatment control Any psychiatric social disease may interfere study followup HIV , B C hepatitis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>Lenalidomide</keyword>
	<keyword>Refractory Cutaneous Lupus</keyword>
</DOC>